In addition, we identified a set of co-expressed genes enriched for SRY targets that exhibits differential survival among low-grade glioma patients on temozolomide, and previous studies have shown a link between the SRY pathway and sensitivity to temozolomide23–25. This evidence concerns the gene SRY and central nervous system cancer.